<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151827</url>
  </required_header>
  <id_info>
    <org_study_id>SE-866/43</org_study_id>
    <nct_id>NCT00151827</nct_id>
  </id_info>
  <brief_title>Olmesartan Medoxomil in Hypertension and Renal Impairment</brief_title>
  <official_title>Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sankyo Pharma Gmbh</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study in hypertensive patients with mild to moderate renal impairment. The
      antihypertensive efficacy of olmesartan medoxomil is compared to losartan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean sitting diastolic blood pressure (dBP), assessed by conventional blood pressure measurements after 12 weeks of treatment</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean sitting diastolic blood pressure, assessed by conventional blood pressure measurements after 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks of treatment;</measure>
    <time_frame>Baseline to 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean sitting systolic blood pressure, assessed by conventional blood pressure measurements after 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks of treatment;</measure>
    <time_frame>Baseline to 1, 2, 3, 8, 18, 24, 30, 36, 44 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment after 1, 2, 4, 8, 12, 18, 24, 30, 36, 44 and 52 weeks of treatment;</measure>
    <time_frame>Baseline to 1, 2, 4, 8, 12, 18, 24, 30, 36, 44 and 52 weeks</time_frame>
    <description>Response to treatment = mean sitting diastolic blood pressure less than or equal to 90 mmHg or reduction greater than or equal to 10 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in creatinine clearance after 12 and 52 weeks of treatment, changes in proteinuria after 4, 12, 24, 36 and 52 weeks of treatment;</measure>
    <time_frame>Baseline to 12 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum creatinine after 12 and 52 weeks of treatment</measure>
    <time_frame>Baseline to 12 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients per dose level after 12 and 52 weeks of treatment</measure>
    <time_frame>Baseline to 12 and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proteinuria after 4, 12, 24, 36 and 52 weeks of treatment</measure>
    <time_frame>Baseline to 4, 12, 24, 36 and 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">393</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan oral tablets 20 mg or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan over encapsulated tablets 50 mg and 100 mg plus olmesartan placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
    <description>Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.</description>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Medications are taken once daily before breakfast with water.</description>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide oral tablets</intervention_name>
    <description>If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator</description>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mean sitting BP prior to randomization of 140-180/90-109 mmHg;

          -  Renal impairment prior to randomization of mild (50 ≤ CLcr ≥ 80 mL/min) to moderate
             (30 ≤ CLcr ≥50 mL/min) severity

        Exclusion Criteria:

          -  Malignant hypertension or sitting BP greater than 180/109 mmHg;

          -  Severe heart failure, severe renal disease;

          -  Recent history of myocardial infarction, stroke or transient ischemic attack;

          -  History, clinical or current evidence of any significant gastrointestinal,
             respiratory, hematological, metabolic, immunological or any other underlying disease
             which in the opinion of the investigator would interfere with the patient's
             participation in the trial;

          -  Hypersensitivity or contraindications to ARBs or ACE inhibitors or any cross allergy;

          -  Treatment with dis-allowed medication;

          -  Pregnant or breastfeeding females or females of childbearing potential without
             adequate contraception;

          -  History of drug and/or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P. U. Witte, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMFORM GmbH, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>October 13, 2010</last_update_submitted>
  <last_update_submitted_qc>October 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

